The cost of Xeljanz 11 mg can vary depending on several factors, including insurance coverage, pharmacy, and location. Manufacturer coupons or patient assistance programs may also be available to help reduce out-of-pocket expenses.
How much does Xeljanz 11 mg cost without insurance?
Without insurance, a 30-day supply of Xeljanz 11 mg can cost several thousand dollars. For example, pricing data from early 2024 indicated that a 30-count of 11 mg extended-release tablets could range from approximately $5,000 to over $6,000 [1]. These figures are estimates, and actual prices may differ.
Can I get financial assistance for Xeljanz?
Yes, financial assistance options may be available for Xeljanz. Pfizer, the manufacturer, offers programs like the Xeljanz Savings Card, which can reduce co-pays for eligible commercially insured patients. Eligibility requirements apply, and the specific savings amount can vary [2]. Patients who are uninsured or underinsured may also qualify for other patient assistance programs, which can be explored through the manufacturer or by consulting with a healthcare provider or pharmacist.
What are the different Xeljanz formulations and their costs?
Xeljanz is available in different strengths and formulations, including tablets and oral solutions, for various indications. The 11 mg extended-release tablet is typically used for ulcerative colitis [3]. Other strengths, such as 5 mg and 10 mg tablets, are prescribed for conditions like rheumatoid arthritis and psoriatic arthritis, and their pricing may differ [3].
When do Xeljanz patents expire?
Patent expiration dates are crucial for determining when generic or biosimilar versions of a drug might become available, potentially impacting pricing. Information on Xeljanz's patent landscape, including expiration timelines, can be accessed through specialized resources [4]. DrugPatentWatch.com provides detailed patent information for many pharmaceuticals.
What are the approved uses for Xeljanz?
Xeljanz (tofacitinib citrate) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [3]. The 11 mg extended-release tablet specifically has an indication for ulcerative colitis [3].
---
Sources:
[1] https://www.goodrx.com/xeljanz
[2] https://www.xeljanz.com/savings-and-support
[3] https://www.xeljanz.com/all-about-xeljanz/how-xeljanz-works
[4] https://drugpatentwatch.com/